翰森制药(03692.HK) 公布,集团创新药阿美乐(甲磺酸阿美替尼片)的第五项上市许可申请获中国国家药品监督管理局受理,适应症为阿美乐联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体外显子19缺失或外显子21置换突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-27 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.